Repros Therapeutics Inc. clinical trials

Acquired by AbbVie, May 8, 2020 · source ↗

The registry lists 58 studies whose lead sponsor is Repros Therapeutics Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 23, 2019.

Studies

Recruiting first, then most recently updated. Showing 50 of 58. List all 58 → · All AbbVie studies →

• Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic EndometriosisCompletedNCT01728454Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsTerminatedNCT02811159Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg EnclomipheneCompletedNCT02651688Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine FibroidsCompletedNCT02323646Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Proellex® Pharmacokinetic Bridging Study IICompletedNCT00620503Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsCompletedNCT02301897Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003CompletedNCT00958334Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Comparison of Two Formulations of AndroxalCompletedNCT01984398Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Crossover Study of the Safety and PK Properties of Proellex®CompletedNCT00749879Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension StudyTerminatedNCT00958412Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)CompletedNCT01386606Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical TestosteroneCompletedNCT00706719Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary HypogonadismCompletedNCT01739595Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary HypogonadismCompletedNCT01532414Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral AdministrationCompletedNCT02274181Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%CompletedNCT01993225Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%CompletedNCT01993212Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of AndroxalCompletedNCT02169804Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary HypogonadismCompletedNCT01619683Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Comparison of Two Formulations of Proellex for Oral AdministrationCompletedNCT02141061Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine FibroidsCompletedNCT01451424Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy AdultsCompletedNCT00741273Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy FemalesTerminatedNCT00787618Phase 1/2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Study to Evaluate Menses Induction in Women Administered ProellexTerminatedNCT00881608Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic EndometriosisTerminatedNCT00556075Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 ExtTerminatedNCT00958893Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female SubjectsCompletedNCT00741468Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine FibroidsTerminatedNCT01069120Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine FibroidsTerminatedNCT00737282Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00853567Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00683917Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine FibroidsTerminatedNCT00785356Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine FibroidsTerminatedNCT00702702Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine FibroidsTerminatedNCT00735553Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy MalesCompletedNCT01991327Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Study to Evaluate the Effect of Food Upon the Pharmacokinetics of AndroxalCompletedNCT02146391Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal FunctionCompletedNCT01923857Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of AndroxalCompletedNCT01959685Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• A Safety and Pharmacokinetic Study of Proellex®CompletedNCT00619385Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Determination of the Lowest, Safe and Effective Dose of ProellexCompletedNCT01187043Phase 1/2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Normalization of Morning Testosterone Levels in Men With Secondary HypogonadismCompletedNCT01270841Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes MellitusCompletedNCT01191320Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary HypogonadismCompletedNCT01534208Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy FemalesCompletedNCT00881062Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Study of Proellex in Pre-menopausal Women With Symptomatic Uterine FibroidsCompletedNCT00882258Phase 2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Proellex Pharmacokinetics Bridging StudyCompletedNCT01067807Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic LeiomyomataCompletedNCT01069094Phase 1/2

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary HypogonadismCompletedNCT01067365Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid SymptomsWithdrawnNCT00874302Phase 3

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie

• A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male SubjectsCompletedNCT02117830Phase 1

  Sponsor listed in the registry: Repros Therapeutics Inc. · First submitted before Repros Therapeutics Inc. became part of AbbVie